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Purpose. To prepare polymeric vesicles and niosomes bearing glucose
or transferrin ligands for drug targeting.
Methods. A glucose-palmitoyl glycol chitosan (PGC) conjugate was
synthesised and glucose-PGC polymeric vesicles prepared by sonica-
tion of glucose-PGC/ cholesterol. N-palmitoylglucosamine (NPG)
was synthesised and NPG niosomes also prepared by sonication of
NPG/ sorbitan monostearate/ cholesterol/ cholesteryl poly-24-
oxyethylene ether. These 2 glucose vesicles were incubated with col-
loidal concanavalin A gold (Con-A gold), washed and visualised by
transmission electron microscopy (TEM). Transferrin was also con-
jugated to the surface of PGC vesicles and the uptake of these
vesicles investigated in the A431 cell line (over expressing the trans-
ferrin receptor) by fluorescent activated cell sorter analysis.
Results. TEM imaging confirmed the presence of glucose units on the
surface of PGC polymeric vesicles and NPG niosomes. Transferrin
was coupled to PGC vesicles at a level of 0.60 ± 0.18 g of transferrin
per g polymer. The proportion of FITC-dextran positive A431 cells
was 42% (FITC-dextran solution), 74% (plain vesicles) and 90%
(transferrin vesicles).
Conclusions. Glucose and transferrin bearing chitosan based vesicles
and glucose niosomes have been prepared. Glucose bearing vesicles
bind Con-A to their surface. Chitosan based vesicles are taken up by
A431 cells and transferrin enhances this uptake.
KEY WORDS: polymeric vesicles; glucose vesicles; transferrin
vesicles.
INTRODUCTION
Actively targeted therapies have demonstrated their po-
tential in the tumour targeting of polymeric gene delivery
systems (1), the central nervous system targeting of peptide
analgesics (2) and the targeting of oligonucleotides to the
liver hepatocytes and macrophages (3). In our laboratories
polymeric vesicles for drug delivery have been developed
from a specially designed amphiphilic chitosan derivative-
palmitoyl glycol chitosan (PGC) (4). While the passive tar-
geting of anti-cancer phospholipid vesicles (liposomes) (5,6)
and non-ionic surfactant vesicles (niosomes) (7) to solid tu-
mours has been well documented, liposomes for gene delivery
are predominantly passively targeted to the lung endothelium
(8,9). Hence, depending on their potential use it will be nec-
essary to elucidate active targeting strategies for vesicular sys-
tems. Additionally the targeting of large hydrophilic mol-
ecules across the blood brain barrier (BBB) is invariably
problematic. Transferrin bearing proteins however may be
targeted across the blood brain barrier when administered via
the carotid artery (10) and the exploitation of the BBB glu-
cose transporter, GLUT-1 (11,12), using glucose peptide con-
jugates results in peptide delivery to the central nervous sys-
tem (2). The GLUT-1 receptor is also over expressed in some
tumour tissue (13,14), hence a glucose targeting ligand may be
useful for targeting anti-cancer genes to tumour tissue. It is
possible that the active targeting of polymeric vesicles for
drug/ gene delivery may be accomplished with targeting li-
gands. This work reports on the preparation and characteri-
sation of polymeric vesicles and niosomes bearing targeting
ligands.
MATERIALS AND METHODS
Materials
Palmitic acid N-hydroxysuccinimide, glucosamine, sorbi-
tan monostearate (Span 60), cholesterol, glycol chitosan (Mw
4 164,000), concanavalin A gold (Con A-gold, 20nm), b-D-
glucopyranosyl phenylisothiocyanate, N-N-diisopropylethyl-
amine, dimethyl-suberimidate (DMSI), triethanolamine, fluo-
rescein isothiocyanate dextran (FITC-dextran), phosphate
buffered saline (PBS, pH 4 7.4) tablets, iron-saturated hu-
man transferrin (TF), Folin Ciocalteu’s reagent, uranylfor-
mate, sodium carbonate, sodium potassium tartrate and cu-
pric sulphate, were all purchased from Sigma Aldrich Co,
UK. Dialysis tubing was obtained from Medicell Interna-
tional, UK. Chloroform, isopropanol, dimethylsulphoxide
(DMSO) and diethylether were all purchased from Merck,
UK. Cholesteryl poly-24-oxyethylene ether (Solulan C24)
was kindly donated by D.F. Anstead, UK. All tissue culture
reagents were obtained from Gibco, UK.
Preparation of Glucose-Bearing Niosomes
Synthesis of N-Palmitoyl Glucosamine (NPG)
This was prepared in a similar manner to that described
for the glycoside palmitoyl muramic acid (15) and was derived
from the method of Lapidot and others (16). Glucosamine
(86.3mg) was dissolved in dimethylsulphoxide (15mL) and
triethanolamine (93mL). To this was added palmitic acid N-
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hydroxysuccinimide (283mg) dissolved in chloroform (4mL).
The mixture was stirred at room temperature for 48 h, pro-
tected from light. Chloroform was evaporated off at room
temperature and the remaining liquid freeze-dried. The re-
sulting powder was purified by washing consecutively with
water (200 ml), chloroform (50 ml), and ether (200 ml) and
then was freeze-dried again. NPG (Figure 1) was obtained as
a white powder.
1H NMR Analysis of NPG
1H NMR (with integration) and 1H correlation spectros-
copy experiments (Bruker AMX 400MHz spectrometer,
Bruker Instruments, UK) were performed on NPG solutions
in deuterated DMSO.
Mass Spectrometry
Analysis of NPG was carried out by mass spectrometry
(fast atom bombardment–FAB on a JEOL AX505 mass spec-
trometer, Jeol Instruments, UK).
Preparation of NPG Niosomes
Niosomes were prepared by shaking a mixture of NPG
(16mg), Span 60 (65mg), cholesterol (58mg) and Solulan C24
(54mg) in water (5mL) at 90°C for 1h, followed by probe
sonication (Soniprobe Instruments, UK) for 4 minutes with
the instrument set at 20% of its maximum capacity.
Synthesis of the PGC- Glucose Conjugate
Palmitoyl glycol chitosan (PGC) (Fig. 2) was synthesised
by the reaction of glycol chitosan with palmitic acid N-
hydroxysuccinimide in a 4:1 sugar monomer, palmitic acid
molar ratio and characterised by 1H NMR analysis as previ-
ously described (4). PGC - glucose conjugate was prepared
using methods described previously (17). PGC (5mg), b-D-
glucopyranosyl phenylisothiocyanate (5mg) and N-N-
diisopropylethylamine (4ml) were dissolved in DMSO (5mL).
The reaction mixture was stirred at room temperature for
24h, diluted with water (25mL), exhaustively dialysed against
1L of water (over a 24h period with 6 changes), and finally
freeze-dried.
Preparation of Polymeric Glucose Vesicles
Vesicles were prepared by probe sonicating the PGC-
glucose conjugate (4mg) and cholesterol (2mg) in water
(4mL) for 4 min with the instrument set at 20% of its maxi-
mum output. The temperature of the probe sonicated formu-
lation reached a maximum temperature of ~ 60°C. The vesicle
dispersion was then filtered through a 0.45 mm filter.
Preparation Of Control Span 60 Niosomes
Vesicles were prepared by shaking a mixture of Span 60
(73mg), cholesterol (65mg), Solulan C24 (54mg) in water
(5mL) at 90°C for 1h followed by probe sonication for 4
minutes with the instrument set at 20% of its maximum ca-
pacity.
Transmission Electron Microscopy (TEM)
The presence of glucose on the vesicle surface was evalu-
ated by incubation with a colloidal dispersion of Con A-gold
thus exploiting the affinity of the lectin concanavalin A for
glucose (18). Glucose bearing vesicles and control plain Span
60 niosome suspensions (0.1mL) were shaken with the Con
A-gold dispersion (0.1mL) at 60°C for 1h. To separate un-
bound Con A-gold from bound Con A-gold, the mixture was
then centrifuged (1,000g for 10 min, Beckman L8-55 ultracen-
trifuge, Beckman Instruments, UK) and the pelleted unbound
Con A-gold discarded. Vesicles bearing the bound gold were
then imaged by TEM as follows. Droplets of the vesicle
preparation were mixed in equal (20 ml) volumes with 1%
uranylformate (pH 4.8) on a specimen support grid and im-
mediately dried down using filter paper. The negatively
stained grid samples were then imaged on a LEO 902 energy
filtering electron microscope at 80 kV.
Preparation of TF-Bearing Polymeric Vesicles Entrapping
the Fluorescent Marker FITC-Dextran
Preparation of Plain PGC Vesicles
PGC vesicles were prepared from PGC and cholesterol
as previously described (4), by probe sonicating PGC (10mg)
and cholesterol (4mg) in PBS (pH 4 7.4, 2mL) for 4 min with
the instrument set at 20% of its maximum capacity.
Conjugation of TF to PGC Vesicles (TF-PGC)
TF was linked with PGC vesicles by using DMSI as a
cross-linking reagent (19) in a similar manner to that reported
for TF-coated liposomes (20). To 2mL of the vesicle suspen-
sion (2mL), obtained from above (5mg mL−1), was added TF
(12mg) and DMSI (24mg) in triethanolamine HCl buffer (pH
7.4, 2mL). The coupling reaction was allowed to take place at
room temperature for 2h whilst stirring. Free TF was then
removed by ultracentrifugation (2 × 150,000g for 1h). After
each ultracentrifugation step the pelleted vesicles were resus-
pended in PBS (pH 4 7.4, 2mL).Fig. 1. Chemical structure of N-palmitoyl glucosamine (N-PG).
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Assay for Conjugated TF
The amount of conjugated TF was determined using the
Lowry method (21). TF bearing vesicle suspensions, blank
vesicles bearing no TF and vesicle suspensions carried
through the TF conjugation reaction but without the cross-
linking agent DMSI were used in this assay. The latter vesicles
were used to ensure that TF was not merely adsorbed to the
vesicle surface. To sodium carbonate solution (25mL, 2%w/v
in NaOH 0.1M) was added sodium potassium tartrate (0.5mL,
2%w/v) and cupric sulphate (0.5mL, 1%w/v) with constant
stirring to avoid precipitation. To 1mL of this solution
(freshly prepared) was added 100ml of each of the vesicle
suspensions (5mg mL−1 PGC) or the standard TF solutions
(0–0.5mg mL−1) and the mixture allowed to stand for 10min.
To these samples was then added Folin Ciocalteu’s reagent
(100mL) with immediate vortexing. All samples were subse-
quently left to stand for 30min and the colour reaction quan-
tified by measuring the absorbance at 750nm (UV-1, Unicam
Ltd., UK). The sample derived from the blank vesicles not
containing TF was used in the reference cell, when measuring
the absorbance of the vesicle samples. The amount of protein
associated with the vesicles was determined with reference to
the standard TF solutions.
Loading of FITC-Dextran TF-PGC Vesicles
FITC-dextran loaded TF-PGC vesicles were prepared by
probe sonicating on ice TF-coated vesicles, obtained as de-
scribed above in a solution of FITC-dextran (2mL, 6mg
mL−1). Unentrapped FITC-dextran was removed by ultracen-
trifugation (150,000g × 1h) and the FITC-dextran loaded
vesicle pellet resuspended in PBS (2mL).
Assay for the Amount of FITC-Dextran Entrapped by
TF- PGC Vesicles
PGC vesicles were disrupted by adding the vesicle sus-
pension (0.1mL) to isopropanol (1mL). This solution was
then diluted to 10mL with PBS (pH 4 7.4) and the fluores-
cence measured (Perkin Elmer LS-50 fluorescence spectrom-
eter, Perkin-Elmer Instruments, UK.) at an excitation wave-
length of 480nm and an emission wavelength of 560nm. The
amount FITC-dextran was computed with reference to stan-
dard solutions of FITC-dextran (11mg mL−1–11mg mL−1) in
an isopropanol, PBS (pH 4 7.4) mixture (10: 90).
Vesicle Sizing
Vesicle sizing was performed by photon correlation spec-
troscopy on a Malvern Zetasizer 1 (Malvern Instruments,
UK.).
Cellular Uptake of FITC-Dextran Loaded
TF- PGC Vesicles
The A431-human epidermoid carcinoma cell line (ATCC
CRL-1555) (22,23) was grown as a monolayer culture at 37°C
in 5% CO2 and maintained by regular passages in Dulbecco‘s
medium supplemented with 10% foetal bovine serum, L-
glutamine (1%w/v). Plated A 431 cells (105 cells/well) were
incubated (37°C for 4 h) with transferrin-bearing vesicles (0.2
mL, 104mg mL−1 PGC) loaded with FITC-dextran (24mg
mL−1), blank FITC-dextran vesicles or with FITC-dextran so-
lution. The concentration of FITC-dextran was the same for
all the samples.
For the microscopic studies cells were grown and exam-
Fig. 2. Chemical structure of palmitoyl glycol chitosan (PGC).
Dufes et al.1252
Fig. 3. Continued on facing page.
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Fig. 3. Transmission electron micrographs with negative staining of Con A-gold (20 nm) associated with a)
N-PG vesicles, b) PGC- glucose vesicles, and c) plain Span 60 niosomes. Gold particles are indicated by
arrow , bar 4 100nm.
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ined on coverslips. At the end of the incubation period, cells
were washed with PBS (pH 4 7.4), transferred to a holder
where the cells were immersed in PBS (pH 4 7.4) and ex-
amined using confocal microscopy (lex4 488 nm, Biorad 600
confocal microscope, Biorad, UK). For flow cytometry stud-
ies, the cells were trypsinised after the incubation period,
washed (PBS , pH 4 7.4) and pelleted (1,000g) twice. Cellular
FITC-dextran uptake was examined on a FACStar flow cy-
tometer (Becton-Dickinson Instruments, UK). The forward
scatter (FSC) and sideward scatter (SSC) of a control cell
suspension was used to discriminate cells and debris. 20,000
cells (gated events) were counted for each sample.
FITC−dextran fluorescence was detected with logarithmic
settings (FL1, lem4 515–545 nm). Cells were counted as posi-
tive when their fluorescence (FL1) was higher than that of
95% of cells from an untreated cell suspension, (i.e. channel
198 to 1024)
RESULTS
Glucose Bearing Vesicles
NPG Niosomes
The characterisation of PGC was as previously described
(4). Proton assignments by 1H NMR of NPG were as follows:
d 0.86 ppm 4 CH3 (palmitoyl), d 1.25 ppm 4 CH2 (palmi-
toyl), d 1.89 ppm 4 CH2 (palmitoyl shielded by carbonyl), d
2.14 ppm 4 CH2 (adjacent to carbonyl protons), d 2.71 ppm
4 CH (C2 sugar proton), d 3.3–4.0 ppm 4 non-exchangeable
sugar protons. Mass spectrometry data yielded one main peak
corresponding to the mass ion 418 (100%, M+) and further
minor peaks 400 (72.75 %, M+ -OH) and 432 (24.43%, M+ +
OH). These results indicate that NPG was successfully pre-
pared.
Stable vesicles could be formed from NPG, sorbitan
monostearate, cholesterol, Solulan C24 (10: 40: 40: 10
mole%). Higher levels of NPG resulted in unstable formula-
tions with the NPG crystallising out of the formulation within
hours. Glucose niosomes prepared from NPG had a z-average
mean diameter of 164nm.
Glucose-PGC Vesicles
Polymeric (PGC) glucose bearing vesicles had a z-
average mean diameter of 155nm.
Con-A Gold Binding
Both types of vesicles effectively bound Con A-gold
while the control plain vesicles (devoid of glucose) did not
(Figure 3), indicating the presence of accessible glucose units
on the surface of these niosomes and polymeric vesicles.
Transferrin Bearing PGC Vesicles
Transferrin was successfully conjugated to PGC in these
vesicles, as determined by the Lowry assay at a level of 0.60 ±
0.18g of TF per g polymer (50 ± 15% of the initial transferrin
used). FITC-dextran was entrapped in the transferrin bearing
vesicles (0.23g per g polymer, corresponding to 10% of the
initial FITC-dextran) and in the plain chitosan based vesicles
(0.32g per g polymer, corresponding to 13% of the initial
FITC-dextran). Plain PGC vesicles had a z-average mean di-
ameter of 420nm, while TF-PGC vesicles had a z-average size
of 458nm and TF-PGC vesicles loaded with FITC-dextran
had a z-average size of 740nm.
Cellular Uptake of Fluorescently Labelled
TF-PGC Vesicles
Fluorescence microscopy images showed a brighter fluo-
rescence (more fluorescently labelled vesicles) associated
with cells incubated with the transferrin bearing vesicles when
compared to the plain vesicles (Figure 4). Flow cytometry
data (Fig. 5) also indicated that there was the greater per-
centage of positive cells when the transferrin bearing vesicles
were incubated with the cells. However it is interesting to
note that the polymeric vesicles without TF also associated to
a greater degree with the cells than the fluorescent marker
(FITC-dextran) in solution. This is indicative of the fact that
these latter vesicles are also taken up by the cells or at least
enhance the uptake of the fluorescent polymer.
DISCUSSION
This work is the first report of the preparation of poly-
meric chitosan based vesicles bearing targeting ligands. In
addition the synthesis of a new surfactant NPG is described.
The synthesis is a simple one-step procedure unlike the syn-
thetic methods previously reported (24). Stable vesicles could
not be produced from this surfactant alone or in the presence
of cholesterol and the incorporation of more than 10mole%
NPG into the bilayer of niosomes resulted in NPG crystallis-
ing out within hours. 6-O-alkanoyl-a-D glucose amphiphiles
also crystallise out of niosomes prepared with these agents
and cholesterol within 3–4 weeks (25). Small niosomes in the
colloidal size range may be formed with this new amphiphile,
NPG. 1-alkyl glucosides have been reported to form large
unilamellar niosomes by Kiwada and others (26). These latter
niosomes are 1mm in diameter and were reported to be stable
when stored in the dark for up to 25 weeks. The production of
colloidal dispersions of the 1-alkyl glucoside niosomes was
not however reported by these authors. To our knowledge
this is the first report of the production of sub-micron glucose
vesicles in which the glucose units are found to be recognis-
able by the glucose specific lectin-con A. Con A served as a
model for the glucose specific receptor.
The PGC-glucose conjugate produced vesicles with a
smaller z-average mean diameter than vesicles produced from
plain PGC (155nm vs 420nm). The conjugation of glucose to
PGC probably resulted in an increase in the size of the hy-
drophilic portion of the molecule relative to the hydrophobic
portion of the molecule. An increase in the hydrophilic head
group of an amphiphile or mixture of amphiphiles would re-
sult in an increase in vesicle curvature and hence a decrease in
vesicle size (27). It appears that with amphiphilic pendant like
polymers, a similar increase in the hydrophilic head group
area also decreases vesicle size. Vesicles incorporating only 10
mole % of NPG are able to bind Con A, as do vesicles pre-
pared from the PGC-glucose conjugate (Figure 3). This indi-
cates that the glucose units were accessible on the vesicle
surface and may be accessible to glucose receptors in vivo.
Because human cancer cells have an enhanced need for glu-
cose and hence frequently over express the GLUT receptors
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Fig. 4. Fluorescence micrographs of A 431 tumour cells treated with a) plain FITC-
dextran loaded vesicles (without transferrin) and b) transferrin bearing FITC-dextran
loaded vesicles, bar 4 100 nm.
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(14), these glucose bearing vesicles may prove useful as gene
targeting agents to tumour cells over-expressing the GLUT
receptor isoforms. In addition the presence of GLUT 1 re-
ceptors at the BBB (28) may potentially be exploited with
these carriers, causing them to increase the transfer of large
hydrophilic molecules across the BBB.
Transferrin was coupled to the surface of the polymeric
vesicles and appeared to be accessible to the TF receptor in
the A431 cell line (Figures 4 and 5). Transferrin receptors are
also over expressed on the surface of many proliferating cells
(29) and their presence may be exploited for the targeting of
gene expression to tumours (1). In addition the administra-
tion of transferrin-protein conjugates via the carotid artery
resulted in the enhanced transfer of large proteins across the
BBB (10). These transferrin bearing vesicles may thus find a
use in the targeting to the central nervous system.
CONCLUSION
Glucose niosomes and glucose or transferrin bearing
polymeric vesicles have been successfully prepared for drug
targeting. The accessibility of these targeting ligands to the
glucose specific lectin Con A or to the transferrin receptor
have been demonstrated. In addition the encapsulation of
FITC-dextran within polymeric vesicles has been shown to
promote the uptake of the fluorescent marker. Further stud-
ies on the usefulness of these new vesicles in vivo are planned
for the very near future.
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